Melphalan-Based Reduced-Intensity Conditioning Is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematologic malignancies are more prevalent in older patients, and because of the increased rate of elderly in the population, the number of patients presenting with hematologic malignancy has increased [1]. The median ages of patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), which are the most common indication for allogeneic hematopoietic transplantation (alloHCT), in this population are 69 and 76 years, respectively [2-4]. Despite the advent of the novel agents, alloHCT remains the only curative option for most of the common hematologic malignancies.

Source: Biology of Blood and Marrow Transplantation - May 9, 2018 Category: Hematology Authors: Monzr M. Al Malki, Nitya Nathwani, Dongyun Yang, Saro Armenian, Sanjeet Dadwal, Jaroslava Salman, Sally Mokhtari, Thai Cao, Karamjeet Sandhu, Michelle Rouse, Matthew Mei, Haris Ali, Pablo Parker, Joseph Alvarnas, Eileen Smith, Margaret O. Donnell, Guido M Source Type: research